News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HUGE short position here - 40% of the float!
Earnings report is due next week. Should be very positive with 2020 forecasts slated!
http://shortsqueeze.com/?symbol=cats&submit=Short+Quote%E2%84%A2
CATS buy 13.71
normal chart
log chart
|
Followers
|
22
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
438
|
|
Created
|
12/09/07
|
Type
|
Free
|
| Moderators | |||
Hythiam, Inc. provides through its Catasys® subsidiary, specialized behavioral health management services to health plans, employers and unions through a network of licensed and company managed health care providers. The Catasys Substance Dependence Program was designed to address substance dependence as a chronic disease. The program seeks to lower costs and improve member health through the delivery of integrated medical and psychosocial interventions in combination with long term care coaching, including the proprietary Prometa® Treatment Program for alcoholism and stimulant dependence. The Prometa Treatment Program, which integrates behavioral, nutritional, and medical components, is also available on a private-pay basis through licensed treatment providers.
Providing specialized behavioral health management services to health plans, employers and unions through a network of licensed and company managed health care providers.
For more info CatasysHealth.com
Hythiam Leadership Team |  | |||||||||||||||||||||||
| Terren S. Peizer
Terren S. Peizer is the founder of our company and has served as our chief executive officer and chairman of our Board of Directors since our inception in February 2003. He has served as Managing Director of Socius Capital Partners, LLC, since September 2009. Mr. Peizer has served on the board of Xcorporeal, Inc. since August 2007 and was executive chairman until October 2008. Mr. Peizer also served as chief executive officer of Clearant, Inc., a company which he founded in April 1999 to develop and commercialize a universal pathogen inactivation technology, until October 2003. He served as chairman of its board of directors from April 1999 to October 2004 and as a director until February 2005. In addition, from June 1999 through May 2003 he was a director, and from June 1999 through December 2000 he was chairman of the board, of supercomputer designer and builder Cray Inc., a NASDAQ Global Market company. Mr. Peizer has been the largest beneficial stockholder and has held various senior executive positions with several technology and biotech companies. He has assisted companies by assembling management teams, boards of directors and scientific advisory boards, formulating business and financial strategies, and investor relations. Mr. Peizer has a background in venture capital, investing, mergers and acquisitions, corporate finance, and previously held senior executive positions with the investment banking firms Goldman Sachs, First Boston and Drexel Burnham Lambert. He received his B.S.E. in Finance from The Wharton School of Finance and Commerce.
Rick A. Anderson
Richard A. Anderson has more than fifteen years of experience in business development, strategic planning and financial management. He has served as a director since July 2003 and an officer since April 2005. He was the chief financial officer of Clearant, Inc. from November 1999 until March 2005, and served as a director from November 1999 to March 2006. Mr. Anderson was previously a director and founding member of PriceWaterhouseCoopers LLP’s, Los Angeles office transaction support group, where he was involved in operational and financial due diligence, valuations and structuring for high technology companies. He received a B.A. in Business Economics from University of California, Santa Barbara.
Peter Donato
Peter Donato has nearly 20 years of progressive financial management experience in large, publicly traded companies as well as small, entrepreneurial companies. He began his career in public accounting with Ernst & Young, and most recently served as CFO of Iris International, a NASDAQ traded medical diagnostics equipment manufacturer, and CFO of Gamma Medica-Ideas, an early stage medical imaging company. He is credited for establishing a strong and timely reporting structure, improved control environment, recruiting and retaining strong accounting, finance and IT teams, as well as developing and maintaining strong relationships with external stakeholders including: investors, coverage analysts, bankers, insurance brokers and auditors. He has held positions with increasing responsibilities at General Motors, Honda, Scotts-Miracle Gro, and Accellent. Mr. Donato graduated from The Ohio State University with a BS in Business Administration and earned an MBA from the University of Akron.
Gary Ingenito, MD, PhD
Dr. Ingenito is responsible for preclinical and clinical scientific research and development. He is a member of the senior executive management team, providing strategic direction for future clinical trials, clinical product development, creation of expanded patient treatment algorithms, data analysis and reporting. Dr. Ingenito previously held executive positions at Angiotech, SFBC International, Otsuka Pharmaceuticals, Corning-Besselaar, and Novartis. A neurologist, Dr. Ingenito
Mr. McLane is responsible for the overall sales and marketing efforts of the company, encompassing customer acquisition, marketing strategy, market research, member outreach and account management. Prior to joining the company he led the marketing activities for Magellan Health Services and founded Optimized Benefits, Inc., a health benefits company that replaced the one-size-fits-all HMO, PPO and CDHP plans with “Life Stage” plans which address the different needs of employees at various stages of their lives. He also led strategy development and product development for CIGNA and ran consumer products businesses for Procter & Gamble, Campbell Soup and Nabisco. Mr. McLane earned a Bachelor of Science degree from The Wharton School of the University of Pennsylvania with majors in accounting and decision science, and a Masters of Business Administration from Cornell University with concentrations in management and organizational behavior.
Dr. Weinstein leads the clinical initiatives for the development of clinical products and provides medical leadership for the business development, marketing and site management departments. Dr. Weinstein also serves as the primary clinical liaison to licensees, physician groups, corporate affiliations, managed care organizations, insurers and external affairs. Prior to Catasys, Dr. Weinstein held positions at PacifiCare Behavioral Health/United Behavioral Health, Magellan Behavioral Health and the Chemical Dependence Unit at St. Elizabeth’s Hospital in Chicago. He has also worked in private practice providing individual and group diagnostic and psychotherapeutic services, as well as family therapy. Dr. Weinstein received his M.D. from the Ross University School of Medicine, and completed his internship and residency in psychiatry at Michael Reese Hospital and Medical Center in Chicago. |
Hythiam Board of Directors | | |
| Terren S. Peizer Chairman and Chief Executive Officer Terren S. Peizer is the founder of our company and has served as our chief executive officer and chairman of our Board of Directors since our inception in February 2003. He has served as Managing Director of Socius Capital Partners, LLC, since September 2009. Mr. Peizer has served on the board of Xcorporeal, Inc. since August 2007 and was executive chairman until October 2008. Mr. Peizer also served as chief executive officer of Clearant, Inc., a company which he founded in April 1999 to develop and commercialize a universal pathogen inactivation technology, until October 2003. He served as chairman of its board of directors from April 1999 to October 2004 and as a director until February 2005. In addition, from June 1999 through May 2003 he was a director, and from June 1999 through December 2000 he was chairman of the board, of supercomputer designer and builder Cray Inc., a NASDAQ Global Market company. Mr. Peizer has been the largest beneficial stockholder and has held various senior executive positions with several technology and biotech companies. He has assisted companies by assembling management teams, boards of directors and scientific advisory boards, formulating business and financial strategies, and investor relations. Mr. Peizer has a background in venture capital, investing, mergers and acquisitions, corporate finance, and previously held senior executive positions with the investment banking firms Goldman Sachs, First Boston and Drexel Burnham Lambert. He received his B.S.E. in Finance from The Wharton School of Finance and Commerce.
Rick A. Anderson President and Chief Operating Officer Rick A. Anderson, has more than fifteen years of experience in business development, strategic planning and financial management. He has served as a director since July 2003 and an officer since April 2005. He was the chief financial officer of Clearant, Inc. from November 1999 until March 2005, and served as a director from November 1999 to March 2006. Mr. Anderson was previously a director and founding member of PriceWaterhouseCoopers LLP’s, Los Angeles office transaction support group, where he was involved in operational and financial due diligence, valuations and structuring for high technology companies. He received a B.A. in Business Economics from University of California, Santa Barbara.  Andrea Grubb Barthwell, M.D., F.A.S.A.M. Andrea Grubb Barthwell, M.D., F.A.S.A.M., is the founder and Chief Executive Officer of the global health care and policy-consulting firm EMGlobal LLC and Director at Two Dreams Outer Banks Treatment Center. President George W. Bush nominated Dr. Barthwell in December 2001 to serve as Deputy Director for Demand Reduction in the Office of National Drug Control Policy (ONDCP). The United States Senate confirmed her nomination on January 28, 2002. As a member of the President's sub-cabinet, Dr. Barthwell was a principal advisor in the Executive Office of the President (EOP) on policies aimed at reducing the demand for illicit drugs. Dr. Barthwell received a Bachelor of Arts degree in Psychology from Wesleyan University, where she serves on the Board of Trustees, and a Doctor of Medicine from the University of Michigan Medical School. Following post-graduate training at the University of Chicago and Northwestern University Medical Center, she began her practice in the Chicago area. Dr. Barthwell served as President of the Encounter Medical Group (EMG, an affiliate of EMGlobal), was a founding member of the Chicago Area AIDS Task Force, hosted a weekly local cable show on AIDS, and is a past president of the American Society of Addiction Medicine. Dr. Barthwell received the Betty Ford Award, given by the Association for Medical Education and Research in Substance Abuse and has been named by her peers as one of the "Best Doctors in America" in addiction medicine.
Marc G. Cummins Marc G. Cummins is a managing partner of Prime Capital, LLC, a private investment firm focused on consumer companies. Prior to founding Prime Capital, Mr. Cummins was managing partner of Catterton Partners, a private equity investor in consumer products and service companies with more than $1 billion of assets under management. Prior to joining Catterton in 1998, Mr. Cummins spent fourteen years at Donaldson, Lufkin & Jenrette Securities Corporation where he was managing director of the Consumer Products and Specialty Distribution Group, and was also involved in leveraged buyouts, private equity and high yield financings. Mr. Cummins received a B.A. in Economics, magna cum laude, from Middlebury College, where he was honored as a Middlebury College Scholar and is a member of Phi Beta Kappa. He also received an M.B.A. in Finance with honors from The Wharton School at University of Pennsylvania.
Jay A. Wolf Jay A. Wolf has served as a director since June 2008. He is the founder and principal of Wolf Capital LP an investment advisory firm he formed in October 2009 to focus on small cap public companies. From November 2003 until September 2009, Mr. Wolf was a partner at Trinad Capital LLC, an activist hedge fund focused on micro-cap public companies. During his work at Trinad, Mr. Wolf assisted distressed and early stage public companies through active board participation, the assembly of management teams and business and financial strategies. Prior to his work at Trinad, Mr. Wolf served as executive vice president of Corporate Development for Wolf Group Integrated Communications Ltd. Prior to that, Mr. Wolf worked at Canadian Corporate Funding, Ltd., a Toronto-based merchant bank as an analyst in the firm’s senior debt department and subsequently for Trillium Growth Capital, the firm’s venture capital fund. Mr. Wolf currently also sits on the boards of Xcorporeal, Inc. (XCR), Zoo Entertainment, Inc. (ZOOE) and NorthStar Systems, Inc. Mr. Wolf is also a member of the board of governors at Cedars-Sinai Hospital. He is a former director of Asianada, Inc., ProLink Holdings Corp., Mandalay Media, Inc., Atrinsic, Inc., Shells Seafood Restaurants, Inc., Optio Software, Inc., Xcorporeal Operations, Inc., Zane Acquisition I, Inc., Zane Acquisition II, Inc., Starvox Communications, Inc. and Noble Medical Technologies, Inc. Mr. Wolf received his B.A from Dalhousie University. Mr. Wolf was chief operating officer and chief financial officer of Starvox Communications, Inc. from March 2005 to March 2007. On March 26, 2008, StarVox Communications, Inc. filed a voluntary petition for liquidation under Chapter 7 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Northern District of California, San Jose. Shells Seafood Restaurants, Inc., a company for which Mr. Wolf formerly served as a director, filed a voluntary petition for reorganization under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Middle District of Florida, Tampa Division, on September 2, 2008. Mr. Wolf’s broad range of investment and operations experience, which includes senior and subordinated debt lending, private equity and venture capital investments, mergers and acquisitions advisory work and public equity investments, equip him with the qualifications and skills to serve on our Board of Directors. |
| Form Type | Received | Period Ending | Size | Report |
|---|---|---|---|---|
| POS AM | Oct 1, 2010 | 49.2 KB |  PDF  RTF  HTML  XLS | |
| POS AM | Oct 1, 2010 | 48.5 KB | PDF RTF HTML XLS | |
| AW | Sept 28, 2010 | 12.6 KB | PDF RTF HTML | |
| AW | Sept 28, 2010 | 12.6 KB | PDF RTF HTML | |
| POS EX | Sept 21, 2010 | 48.6 KB | PDF RTF HTML XLS | |
| POS EX | Sept 21, 2010 | 49.4 KB | PDF RTF HTML XLS | |
| 3 | Sept 3, 2010 | Aug 25, 2010 | 4.3 KB | PDF RTF HTML XLS |
| 8-K | Aug 27, 2010 | Aug 25, 2010 | 38.5 KB | PDF RTF HTML XLS |
| 10-Q | Aug 16, 2010 | Jun 30, 2010 | 1.2 MB | PDF RTF HTML XLS |
| 8-K | Jul 7, 2010 | Jul 7, 2010 | 18.8 KB | PDF RTF HTML XLS |
| Shares Outstanding | 55,154,688 | a/o Apr 28, 2009 |
| American Stock Transfer & Trust Company |
